Literature DB >> 25488879

Cost-value analysis of health interventions: introduction and update on methods and preference data.

Erik Nord1.   

Abstract

According to the consensus statement from the International Society for Pharmacoeconomics and Outcomes Research Quality-Adjusted Life-Year (QALY) workshop in Philadelphia in 2007 "concerns for fairness may cause social resource allocation preferences to deviate considerably from the ranking that consideration of costs per QALY would suggest." Salient concerns for fairness include the view that priority should be given to the severely ill over the less severely ill, that people have a right to realize their potential for health even if their capacity to benefit from treatment is moderate, and that everybody has the same right to treatment that averts premature death, even if their health and functional level is less than perfect. Cost-value analysis incorporates these concerns in formal economic evaluation of health interventions and programs and thus has a potential for ranking interventions and programs in a way that is more consistent with societal values. Data on the strength of public concerns for fairness are now sufficient to be useful in formal economic evaluation. The data may, within a context of fair and open deliberations, help societal decision makers to roughly indicate the societal value of a QALY in different circumstances and thus determine a tentative grading of willingness to pay for a QALY.

Entities:  

Mesh:

Year:  2015        PMID: 25488879     DOI: 10.1007/s40273-014-0212-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

1.  Health state after treatment: a reason for discrimination?

Authors:  J M Abellan-Perpiñan; J L Pinto-Prades
Journal:  Health Econ       Date:  1999-12       Impact factor: 3.046

2.  The measurement of individual utility and social welfare.

Authors:  P Dolan
Journal:  J Health Econ       Date:  1998-01       Impact factor: 3.883

3.  Toward a consensus on the QALY.

Authors:  Michael Drummond; Diana Brixner; Marthe Gold; Paul Kind; Alistair McGuire; Erik Nord
Journal:  Value Health       Date:  2009-03       Impact factor: 5.725

Review 4.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046

5.  Transforming EQ-5D utilities for use in cost–value analysis of health programs.

Authors:  Erik Nord; Rune Johansen
Journal:  Eur J Health Econ       Date:  2015-04

6.  Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

Authors:  E Nord; F Wisløff; M Hjorth; J Westin
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

7.  Methods for measuring levels of well-being for a health status index.

Authors:  D L Patrick; J W Bush; M M Chen
Journal:  Health Serv Res       Date:  1973       Impact factor: 3.402

8.  The validity of using health state indexes in measuring the consequences of traffic injury for public health.

Authors:  R Elvik
Journal:  Soc Sci Med       Date:  1995-05       Impact factor: 4.634

9.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

10.  Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys.

Authors:  E Nord; J Richardson; K Macarounas-Kirchmann
Journal:  Int J Technol Assess Health Care       Date:  1993       Impact factor: 2.188

View more
  6 in total

1.  Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?

Authors:  Jonathan Karnon; Andrew Partington
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

2.  Exclusion Criteria as Measurements II: Effects on Utility Functions.

Authors:  Barry Dewitt; Baruch Fischhoff; Alexander L Davis; Stephen B Broomell; Mark S Roberts; Janel Hanmer
Journal:  Med Decis Making       Date:  2019-08-28       Impact factor: 2.583

3.  Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.

Authors:  Erik Nord
Journal:  Eur J Health Econ       Date:  2017-03-03

4.  Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings.

Authors:  Sarah E Rutstein; Joan T Price; Nora E Rosenberg; Stuart M Rennie; Andrea K Biddle; William C Miller
Journal:  Glob Public Health       Date:  2016-05-04

5.  A spatiotemporal recommendation engine for malaria control.

Authors:  Qian Guan; Brian J Reich; Eric B Laber
Journal:  Biostatistics       Date:  2022-07-18       Impact factor: 5.279

6.  Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Authors:  J Jaime Caro; John E Brazier; Jonathan Karnon; Peter Kolominsky-Rabas; Alistair J McGuire; Erik Nord; Michael Schlander
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.